FDA Requests Warnings on CAR-T Cell Therapies, Citing Secondary Cancers
The Food and Drug Administration is requesting that CAR-T cell therapies now come with a Boxed Warning about secondary malignancies that have been reported in patients who undergo these treatments.
David Mitchell Brucel Levine University Of Pennsylvania Drug Administration National Institutes Of Health Bristol Myers Squibb
Source: curetoday.com